Alwin Krämer - Concepedia

Author

Alwin Krämer

Heidelberg University

Also Known As

A Krämer, A. M. Kramer, Alwin Kramer, Alwin Krämer, Alwin Krämer, Carsten Bokemeyer, Krämer, Alwin, LÃ¶ffler, Harald

273

Publications

12.5K

Citations

H-Index

Concepts

All Affiliations

Heidelberg University German Cancer Research Center University Hospital Heidelberg National Center for Tumor Diseases Goethe University Frankfurt

About

Alwin Krämer is an author at Heidelberg University specializing in medicine, cell biology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	36	6.4K
2	Health Sciences	12	13	1.7K
3	Natural Sciences	6	6	198
4	Biochemistry	3	3	129
5	Engineering	2	2	24

Alwin Krämer

102

Publications

11.2K

Citations

H-Index

Page 1

	Year	Citations
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Jiřina Bártková, Zuzana Hořejšı́, Karen Koed, Nature ChromatinTumor BiologyGenome InstabilityDna DamageOncogenic Agent	2005	2.7K
Prediction of acute myeloid leukaemia risk in healthy individuals Sagi Abelson, Grace Collord, Stanley Ng, Nature Hematological MalignancyHealthy IndividualsMixed-phenotype Acute LeukemiaHematologyOncology	2018	844
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease Stefan Stein, Marion Ott, Stephan Schultze‐Strasser, Nature Medicine Hematological MalignancyAutoimmune DiseaseGranulocyteEvi1 ActivationImmunology	2010	774
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli, The Lancet Oncology Hematological MalignancyMedicineHematologyClinical TrialsMyeloid Neoplasia	2019	465
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Christoph Röllig, Hubert Serve, Andreas Hüttmann, The Lancet Oncology Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematology	2015	395
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, The Lancet Oncology Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyClinical Trials	2018	341
Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase Alwin Krämer, Niels Mailand, Claudia Lukas, Nature Cell Biology Signal TransductionCell RegulationCell DivisionCyclin-b–cdk1 KinaseCell Cycle	2004	337
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial Hubert Serve, Utz Krug, Ruth Wagner, Journal of Clinical Oncology	2013	309
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner, The Lancet Oncology Hematological MalignancyFlt3 InhibitorMedicineHematologyClinical Trials	2018	259
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy Hartmut Döhner, Michael Lübbert, Walter Fiedler, Blood	2014	227

Page 1